Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study

A. Ferrant, M. Labopin, F. Frassoni, H. G. Prentice, J. Y. Cahn, D. Blaise, J. Reiffers, G. Visani, M. A. Sanz, M. A. Boogaerts, B. Löwenberg, N. C. Gorin

Research output: Contribution to journalArticle

Abstract

The presentation cytogenetic result was correlated with outcome for 999 patients with acute myeloblastic leukemia (AML) having bone marrow transplantation (BMT) in first complete remission (CR1). The karyotype at diagnosis was classified according to the modified Chicago classification. Allogeneic BMT (AlloBMT) was performed in 500 patients and autologous BMT (ABMT) in 499 patients. For both groups, an abnormal chromosome (abn) 5 and/or 7 or a hypodiploid karyotype had a poor outcome, whereas t(15;17), pseudodiploidy, hyperdiploidy and diploidy were associated with a standard prognosis. Abn (16) and t(8;21) were also of standard prognosis for ABMT, but favorable for AlloBMT. When comparing AlloBMT and ABMT in patients with favorable or standard cytogenetics, AlloBMT was of benefit for remission duration and leukemia-free survival (LFS). Patients with an unfavorable karyotype had a similar outcome, regardless of type of BMT. By multivariate analysis, cytogenetics at diagnosis had the strongest prognostic value for relapse, LFS, and survival in AlloBMT. In ABMT, cytogenetics influenced relapse and LFS. We concluded that the karyotype at diagnosis had important prognostic implication in AML grafted in CR1.

Original languageEnglish
Pages (from-to)2931-2938
Number of pages8
JournalBlood
Volume90
Issue number8
Publication statusPublished - Oct 15 1997

Fingerprint

Bone Marrow Transplantation
Karyotype
Acute Myeloid Leukemia
Bone
Cytogenetics
Leukemia
Survival
Chromosomes
Recurrence
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Polyploidy
Autologous Transplantation
Homologous Transplantation
Diploidy
Multivariate Analysis

ASJC Scopus subject areas

  • Hematology

Cite this

Karyotype in acute myeloblastic leukemia : Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study. / Ferrant, A.; Labopin, M.; Frassoni, F.; Prentice, H. G.; Cahn, J. Y.; Blaise, D.; Reiffers, J.; Visani, G.; Sanz, M. A.; Boogaerts, M. A.; Löwenberg, B.; Gorin, N. C.

In: Blood, Vol. 90, No. 8, 15.10.1997, p. 2931-2938.

Research output: Contribution to journalArticle

Ferrant, A, Labopin, M, Frassoni, F, Prentice, HG, Cahn, JY, Blaise, D, Reiffers, J, Visani, G, Sanz, MA, Boogaerts, MA, Löwenberg, B & Gorin, NC 1997, 'Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study', Blood, vol. 90, no. 8, pp. 2931-2938.
Ferrant, A. ; Labopin, M. ; Frassoni, F. ; Prentice, H. G. ; Cahn, J. Y. ; Blaise, D. ; Reiffers, J. ; Visani, G. ; Sanz, M. A. ; Boogaerts, M. A. ; Löwenberg, B. ; Gorin, N. C. / Karyotype in acute myeloblastic leukemia : Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study. In: Blood. 1997 ; Vol. 90, No. 8. pp. 2931-2938.
@article{13eace51ee374b488c9cce3d60f120ec,
title = "Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study",
abstract = "The presentation cytogenetic result was correlated with outcome for 999 patients with acute myeloblastic leukemia (AML) having bone marrow transplantation (BMT) in first complete remission (CR1). The karyotype at diagnosis was classified according to the modified Chicago classification. Allogeneic BMT (AlloBMT) was performed in 500 patients and autologous BMT (ABMT) in 499 patients. For both groups, an abnormal chromosome (abn) 5 and/or 7 or a hypodiploid karyotype had a poor outcome, whereas t(15;17), pseudodiploidy, hyperdiploidy and diploidy were associated with a standard prognosis. Abn (16) and t(8;21) were also of standard prognosis for ABMT, but favorable for AlloBMT. When comparing AlloBMT and ABMT in patients with favorable or standard cytogenetics, AlloBMT was of benefit for remission duration and leukemia-free survival (LFS). Patients with an unfavorable karyotype had a similar outcome, regardless of type of BMT. By multivariate analysis, cytogenetics at diagnosis had the strongest prognostic value for relapse, LFS, and survival in AlloBMT. In ABMT, cytogenetics influenced relapse and LFS. We concluded that the karyotype at diagnosis had important prognostic implication in AML grafted in CR1.",
author = "A. Ferrant and M. Labopin and F. Frassoni and Prentice, {H. G.} and Cahn, {J. Y.} and D. Blaise and J. Reiffers and G. Visani and Sanz, {M. A.} and Boogaerts, {M. A.} and B. L{\"o}wenberg and Gorin, {N. C.}",
year = "1997",
month = "10",
day = "15",
language = "English",
volume = "90",
pages = "2931--2938",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Karyotype in acute myeloblastic leukemia

T2 - Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study

AU - Ferrant, A.

AU - Labopin, M.

AU - Frassoni, F.

AU - Prentice, H. G.

AU - Cahn, J. Y.

AU - Blaise, D.

AU - Reiffers, J.

AU - Visani, G.

AU - Sanz, M. A.

AU - Boogaerts, M. A.

AU - Löwenberg, B.

AU - Gorin, N. C.

PY - 1997/10/15

Y1 - 1997/10/15

N2 - The presentation cytogenetic result was correlated with outcome for 999 patients with acute myeloblastic leukemia (AML) having bone marrow transplantation (BMT) in first complete remission (CR1). The karyotype at diagnosis was classified according to the modified Chicago classification. Allogeneic BMT (AlloBMT) was performed in 500 patients and autologous BMT (ABMT) in 499 patients. For both groups, an abnormal chromosome (abn) 5 and/or 7 or a hypodiploid karyotype had a poor outcome, whereas t(15;17), pseudodiploidy, hyperdiploidy and diploidy were associated with a standard prognosis. Abn (16) and t(8;21) were also of standard prognosis for ABMT, but favorable for AlloBMT. When comparing AlloBMT and ABMT in patients with favorable or standard cytogenetics, AlloBMT was of benefit for remission duration and leukemia-free survival (LFS). Patients with an unfavorable karyotype had a similar outcome, regardless of type of BMT. By multivariate analysis, cytogenetics at diagnosis had the strongest prognostic value for relapse, LFS, and survival in AlloBMT. In ABMT, cytogenetics influenced relapse and LFS. We concluded that the karyotype at diagnosis had important prognostic implication in AML grafted in CR1.

AB - The presentation cytogenetic result was correlated with outcome for 999 patients with acute myeloblastic leukemia (AML) having bone marrow transplantation (BMT) in first complete remission (CR1). The karyotype at diagnosis was classified according to the modified Chicago classification. Allogeneic BMT (AlloBMT) was performed in 500 patients and autologous BMT (ABMT) in 499 patients. For both groups, an abnormal chromosome (abn) 5 and/or 7 or a hypodiploid karyotype had a poor outcome, whereas t(15;17), pseudodiploidy, hyperdiploidy and diploidy were associated with a standard prognosis. Abn (16) and t(8;21) were also of standard prognosis for ABMT, but favorable for AlloBMT. When comparing AlloBMT and ABMT in patients with favorable or standard cytogenetics, AlloBMT was of benefit for remission duration and leukemia-free survival (LFS). Patients with an unfavorable karyotype had a similar outcome, regardless of type of BMT. By multivariate analysis, cytogenetics at diagnosis had the strongest prognostic value for relapse, LFS, and survival in AlloBMT. In ABMT, cytogenetics influenced relapse and LFS. We concluded that the karyotype at diagnosis had important prognostic implication in AML grafted in CR1.

UR - http://www.scopus.com/inward/record.url?scp=0030762673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030762673&partnerID=8YFLogxK

M3 - Article

C2 - 9376573

AN - SCOPUS:0030762673

VL - 90

SP - 2931

EP - 2938

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -